From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence...

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) management; however, up to 30-40% of patients experience inadequate response or intolerance, necessitating escalation to advanced therapeutic strategies. Tumor necrosis factor (TNF) inhibitors were the first biologic agents introduced for RA and continue to play an important role in MTX-resistant disease, alongside newer biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).

To synthesize Phase 4 clinical trial evidence published between 2014 and 2024 evaluating therapeutic strategies for MTX-resistant RA, including TNF inhibitor optimization, newer biologic and targeted synthetic DMARDs, adjunctive therapies, and emerging precision medicine approaches.

A systematic review of Phase 4 interventional trials registered on ClinicalTrials.gov was conducted using the keyword "rheumatoid arthritis", with predefined eligibility restrictions applied. Trials enrolling adults with MTX-resistant RA and reporting clinical, safety, biomarker, imaging, or patient reported outcomes were included. Extracted data encompassed study design, intervention type, trial classification (exploratory/mechanistic, optimization/treat to target, or effectiveness/safety), outcomes, and enrolment.

Eighteen Phase 4 trials were identified, encompassing a heterogeneous range of study designs and therapeutic strategies. Optimization and treat-to-target studies demonstrated continued clinical relevance of TNF inhibitors, particularly in combination with MTX. Newer biologic and targeted synthetic DMARDs showed comparable efficacy, while exploratory trials provided mechanistic insights through biomarker and imaging assessments. Safety profiles across trials were generally consistent with established class effects, with infections and laboratory abnormalities most frequently reported and no unexpected safety signals observed.

Phase 4 evidence highlights the continued role of TNF inhibitors alongside newer biologic and targeted synthetic therapies in MTX-resistant RA. Trial heterogeneity reflects real world clinical complexity, underscoring the importance of treatment optimization, safety monitoring, and emerging precision strategies in contemporary RA management.